Any current/future capex/capital investment/strategic investment?

Phase-2 Greenfield project CAPEX planned for FY23 and FY24 is Rs. 300 to 400 crores. Four new plants being installed under this phase: - N-Butylamine plant with 15,000 tons capacity. - Acetonitrile plant with 15,000 tons capacity. - Methylamine plant with 40,000 tons capacity. - DMF plant with 30,000 tons capacity. Production at these plants expected to commence between mid FY24 and end of FY25. Majority of the CAPEX funding will be from internal accruals; minor borrowing possible towards project completion. Plans to expand and diversify the product portfolio with new products like DMC

Future growth expectations in sales/revenue/volumes?

The company conservatively forecasts revenue of Rs. 2,500 crores for the next year, factoring in potential price declines although EBITDA and EPS are expected to remain stable. (Page 15) Full capacity utilization of existing and new plants (N-Butyl Amine, Acetonitrile, Methylamine, DMF) is expected by end of FY25, targeting a revenue of around Rs. 4,000 crores. (Page 14) FY23 standalone revenue is guided between Rs. 2,200 to Rs. 2,300 crores; consolidated revenue should reach Rs. 2,500 crores. (Page 12) Subsidiary's turnover expected to grow to Rs. 700-750 crores in FY23, with capacity util

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue guidance for FY23 is conservative at Rs. 2,500 crores, considering potential price corrections but new products adding to sales. Despite conservative revenue guidance, absolute EBITDA and EPS values are expected to remain stable. EBITDA margin guidance for FY23 is maintained at 24% to 26%, with potential short-term dip during new product market entries but expected recovery thereafter. Expansion includes four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) to be commissioned by end of 2025, targeting a top-line of Rs. 4,000 crores by then. Strong growth potential ant

Current/ Expected Orderbook/ Pending Orders?

The transcript provided in the document "380.pdf" does not explicitly mention the current or expected order book or pending orders for Balaji Amines Limited. However, the company discusses capacity additions, new product launches, and growth expectations indicating a strong demand environment. Ram Reddy mentioned commissioning four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) expected by end of 2025 implying anticipated orders to utilize these capacities. The management is confident about future growth with revenue guidance of Rs. 2,500 crores for the next year, aiming Rs. 4,000

Any current/future new fundraising through debt or equity?

Majority of the planned CAPEX will be funded through internal accruals. A few crores of borrowing might be considered toward the end of the completion phase if required. There is a credit committee in the subsidiary board evaluating options including possible mergers, but no specific mention of fresh equity fundraising. No explicit plans for equity fundraising were disclosed in the provided transcript. Overall, the company appears focused on utilizing internal funds with limited external borrowing potential for near-term investments.

IN US

Sale is live|00:00:00left today

Balaji Amines LtdQ1 FY22Chemicals & Petrochemicals

Balaji Amines Ltd Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,989P/E: 33.1Market Cap: ₹5.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company conservatively forecasts revenue of Rs. 2,500 crores for the next year, factoring in potential price declines although EBITDA and EPS are expected to remain stable. (Page 15)
→Full capacity utilization of existing and new plants (N-Butyl Amine, Acetonitrile, Methylamine, DMF) is expected by end of FY25, targeting a revenue of around Rs. 4,000 crores. (Page 14)
→FY23 standalone revenue is guided between Rs. 2,200 to Rs. 2,300 crores; consolidated revenue should reach Rs. 2,500 crores. (Page 12)
→Subsidiary's turnover expected to grow to Rs. 700-750 crores in FY23, with capacity utilization rising to 70%-80%. (Page 4)
→Volumes are anticipated to grow annually by approximately 10%-15%, with total volumes projected to exceed 1,15,000 metric tons. (Page 8)
→New products like DMC and Propylene Glycol expected to add Rs. 300 crores in revenue once fully operational. (Page 9)
→Export revenue share aimed to increase to 30%-35% of total revenues to mitigate risks related to imported raw materials. (Page 9)

Margin guidance

Category 3

→Revenue guidance for FY23 is conservative at Rs. 2,500 crores, considering potential price corrections but new products adding to sales.
→Despite conservative revenue guidance, absolute EBITDA and EPS values are expected to remain stable.
→EBITDA margin guidance for FY23 is maintained at 24% to 26%, with potential short-term dip during new product market entries but expected recovery thereafter.
→Expansion includes four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) to be commissioned by end of 2025, targeting a top-line of Rs. 4,000 crores by then.
→Strong growth potential anticipated due to 'China Plus One' policy boosting Indian pharma and agrochemical sectors, end-user markets of their specialty chemicals.
→Volumes and capacity utilization expected to improve, supporting sustainable earnings growth.
→The company expects to maintain around 30%-35% of revenue from exports, expanding the market base and earnings.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Majority of the planned CAPEX will be funded through internal accruals.
→A few crores of borrowing might be considered toward the end of the completion phase if required.
→There is a credit committee in the subsidiary board evaluating options including possible mergers, but no specific mention of fresh equity fundraising.
→No explicit plans for equity fundraising were disclosed in the provided transcript.
→Overall, the company appears focused on utilizing internal funds with limited external borrowing potential for near-term investments.

Order book

→The transcript provided in the document "380.pdf" does not explicitly mention the current or expected order book or pending orders for Balaji Amines Limited.
→However, the company discusses capacity additions, new product launches, and growth expectations indicating a strong demand environment.
→Ram Reddy mentioned commissioning four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) expected by end of 2025 implying anticipated orders to utilize these capacities.
→The management is confident about future growth with revenue guidance of Rs. 2,500 crores for the next year, aiming Rs. 4,000 crores post capacity expansion.
→Strong demand is noted in end-user industries with continued growth potential, backed by ‘China plus one’ strategy.
→No specific order book or pending order details were disclosed in the transcript.

Capex plans

Yes

→Phase-2 Greenfield project CAPEX planned for FY23 and FY24 is Rs. 300 to 400 crores.
→Four new plants being installed under this phase:
→ - N-Butylamine plant with 15,000 tons capacity.
→ - Acetonitrile plant with 15,000 tons capacity.
→ - Methylamine plant with 40,000 tons capacity.
→ - DMF plant with 30,000 tons capacity.
→Production at these plants expected to commence between mid FY24 and end of FY25.
→Majority of the CAPEX funding will be from internal accruals; minor borrowing possible towards project completion.
→Plans to expand and diversify the product portfolio with new products like DMC and propylene glycol.
→The company is also evaluating debottlenecking and potential derivatives addition at subsidiaries to grow capacity further.

How does Balaji Amines Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Balaji Amines Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Balaji Amines Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio